PLXNA3

Across TCGA pan-cancer cohorts, PLXNA3 RNA differs between tumor and matched normal tissue in 18 of 18 cancer types tested, making tumor–normal expression one of PLXNA3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PLXNA3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PLXNA3 is over-expressed in tumor.

KIRC, KIRP, and COAD are the cancer types where PLXNA3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLXNA3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.141	<.001	12	view →
KIRP	Female	II,III,IV	+2.056	<.001	11	view →
COAD	All	IV	+1.867	<.001	11	view →
HNSC	Male	III,IV	+1.364	<.001	10	view →
THCA	All	III,IV	+0.863	<.001	10	view →
LIHC	Female	II,III,IV	+1.400	<.001	9	view →
BRCA	All	III,IV	+0.874	<.001	8	view →
LUAD	All	II,III,IV	+0.736	<.001	8	view →
STAD	Male	II,III,IV	+1.640	<.001	6	view →
BLCA	All	All	+0.728	.002	6	view →
CHOL	Male	All	+3.148	<.001	5	view →
READ	All	All	+1.020	.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 18 lineages.

PLXNA3–KIRC

Open the KIRC breakdown →